NO301825B1 - Ringsubstituerte 2-amino-1,2,3,4-tetrahydronaftalener og farmasöytisk preparat inneholdende slike - Google Patents

Ringsubstituerte 2-amino-1,2,3,4-tetrahydronaftalener og farmasöytisk preparat inneholdende slike Download PDF

Info

Publication number
NO301825B1
NO301825B1 NO920489A NO920489A NO301825B1 NO 301825 B1 NO301825 B1 NO 301825B1 NO 920489 A NO920489 A NO 920489A NO 920489 A NO920489 A NO 920489A NO 301825 B1 NO301825 B1 NO 301825B1
Authority
NO
Norway
Prior art keywords
mixture
mmol
propylamino
tetrahydronaphthalene
added
Prior art date
Application number
NO920489A
Other languages
English (en)
Norwegian (no)
Other versions
NO920489L (no
NO920489D0 (no
Inventor
Craig Steven Hoechstetter
Diane Lynn Huser
John Mehnert Schaus
Robert Daniel Titus
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO920489D0 publication Critical patent/NO920489D0/no
Publication of NO920489L publication Critical patent/NO920489L/no
Publication of NO301825B1 publication Critical patent/NO301825B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Lubricants (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
NO920489A 1991-02-08 1992-02-06 Ringsubstituerte 2-amino-1,2,3,4-tetrahydronaftalener og farmasöytisk preparat inneholdende slike NO301825B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65358391A 1991-02-08 1991-02-08

Publications (3)

Publication Number Publication Date
NO920489D0 NO920489D0 (no) 1992-02-06
NO920489L NO920489L (no) 1992-08-10
NO301825B1 true NO301825B1 (no) 1997-12-15

Family

ID=24621480

Family Applications (1)

Application Number Title Priority Date Filing Date
NO920489A NO301825B1 (no) 1991-02-08 1992-02-06 Ringsubstituerte 2-amino-1,2,3,4-tetrahydronaftalener og farmasöytisk preparat inneholdende slike

Country Status (26)

Country Link
US (2) US5426226A (pt)
EP (2) EP0712837B1 (pt)
JP (1) JP3283892B2 (pt)
KR (1) KR100219995B1 (pt)
CN (2) CN1036392C (pt)
AT (2) ATE197145T1 (pt)
AU (2) AU653197B2 (pt)
BR (1) BR9200426A (pt)
CA (1) CA2060815C (pt)
CZ (1) CZ288067B6 (pt)
DE (2) DE69218813T2 (pt)
DK (2) DK0498590T3 (pt)
ES (2) ES2102456T3 (pt)
FI (1) FI920526L (pt)
GR (2) GR3023601T3 (pt)
HU (3) HU221184B1 (pt)
IE (1) IE920417A1 (pt)
IL (3) IL114760A (pt)
MX (1) MX9200505A (pt)
MY (1) MY116454A (pt)
NO (1) NO301825B1 (pt)
NZ (2) NZ241495A (pt)
PT (1) PT712837E (pt)
RU (2) RU2057751C1 (pt)
YU (1) YU48927B (pt)
ZA (1) ZA92767B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0471515T3 (da) * 1990-08-15 1997-07-21 Lilly Co Eli Ringsubstituerede 2-amino-1,2,3,4-tetrahydronphtalener, 3-aminochromaner og 3-aminothiochromaner
NZ241495A (en) * 1991-02-08 1994-10-26 Lilly Co Eli 2-amino-1,2,3,4-tetrahydronaphthalene and 3-aminochromane derivative, preparation and pharmaceutical compositions thereof
US5434174A (en) * 1992-07-17 1995-07-18 Eli Lilly And Company Isoxazole derivatives for the treatment of irritable bowel syndrome
WO1994022495A1 (en) * 1993-03-31 1994-10-13 The Trustees Of The University Of Pennsylvania Dopamine d-3 and serotonin (5-ht1a) receptor ligands and imaging agents
IL110857A0 (en) * 1993-09-09 1994-11-28 Lilly Co Eli Cessation of tobacco use
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
US6355674B1 (en) 1997-04-30 2002-03-12 Eli Lilly And Company Aminotetralins as 5-HT1D α Agonists
EP1052982A4 (en) * 1997-04-30 2004-10-06 Lilly Co Eli AMINOTETRALINS AS AGONISTS OF 5-HT 1D $ g (a)?
WO1999001121A1 (en) 1997-07-01 1999-01-14 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
AU6018799A (en) 1998-09-09 2000-03-27 Ishihara Sangyo Kaisha Ltd. Fused-benzene derivatives useful as herbicides
FR2792529B1 (fr) * 1999-04-26 2001-09-28 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
US6792563B1 (en) * 2000-04-28 2004-09-14 Intel Corporation Method and apparatus for bus activity tracking
EP1474141A1 (en) * 2002-02-13 2004-11-10 Pharmagene Laboratories Ltd 5-ht2b receptor antagonists
SE0301795D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use I
SE0301796D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use II
SE0301794D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use III
SE0301798D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use IV
RU2377556C1 (ru) * 2008-04-02 2009-12-27 ФГУП "Научно-исследовательский институт прикладной акустики" Способ установления отличительных признаков в химическом составе моногенных линий подсолнечника

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ192641A (en) * 1979-01-26 1984-10-19 Hoffmann La Roche Substituted acetophenones and pharmaceutical compositions
SE8004002L (sv) * 1980-05-29 1981-11-30 Arvidsson Folke Lars Erik Terapeutiskt anvendbara tetralinderivat
US4801605A (en) * 1986-08-29 1989-01-31 Ciba-Geigy Corporation 3-amino-dihydro-[1]-benzopyrans and benzothiopyrans
SE8605504D0 (sv) * 1986-12-19 1986-12-19 Astra Laekemedel Ab Novel chroman derivatives
DE3719924A1 (de) * 1986-12-22 1988-06-30 Bayer Ag 8-substituierte 2-aminotetraline
US5214156A (en) * 1988-03-25 1993-05-25 The Upjohn Company Therapeutically useful tetralin derivatives
CA1335591C (en) * 1988-05-23 1995-05-16 James Arthur Nixon Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
CA1335106C (en) * 1989-02-27 1995-04-04 John Mehnert Schaus Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
FR2647365B1 (fr) * 1989-05-24 1991-08-30 Inst Francais Du Petrole Catalyseur multifonctionnel pour le traitement des gaz d'echappement des moteurs a combustion interne, contenant de l'uranium, au moins un promoteur de l'uranium et au moins un metal precieux et sa preparation
SE8901889D0 (sv) * 1989-05-26 1989-05-26 Astra Ab Novel 8-substituted-2-aminotetralines
DE69032725T2 (de) * 1989-05-31 1999-04-08 Pharmacia & Upjohn Co., Kalamazoo, Mich. ZNS-wirksame 8-Heterocyclyl-2-aminotetralin Derivate
DE3919624A1 (de) * 1989-06-15 1990-12-20 Boehringer Ingelheim Kg Neue 2,5-diaminotetraline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
CA2028341A1 (en) * 1989-10-23 1991-04-24 Junichi Sato 5-substituted-2,4-diphenylpyrimidine derivatives, their production and use
SE8904361D0 (sv) * 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
US5420151A (en) * 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
DK0471515T3 (da) * 1990-08-15 1997-07-21 Lilly Co Eli Ringsubstituerede 2-amino-1,2,3,4-tetrahydronphtalener, 3-aminochromaner og 3-aminothiochromaner
NZ241495A (en) * 1991-02-08 1994-10-26 Lilly Co Eli 2-amino-1,2,3,4-tetrahydronaphthalene and 3-aminochromane derivative, preparation and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
EP0498590B1 (en) 1997-04-09
ES2153071T3 (es) 2001-02-16
JP3283892B2 (ja) 2002-05-20
CA2060815C (en) 2002-05-14
IE920417A1 (en) 1992-08-12
DE69218813D1 (de) 1997-05-15
FI920526A0 (fi) 1992-02-07
EP0712837A3 (en) 1997-05-21
DE69218813T2 (de) 1997-08-14
EP0712837A2 (en) 1996-05-22
HU221184B1 (en) 2002-08-28
US5426226A (en) 1995-06-20
NZ264302A (en) 1995-04-27
MX9200505A (es) 1992-08-01
MY116454A (en) 2004-02-28
FI920526A7 (fi) 1992-08-09
IL100858A (en) 1996-03-31
CA2060815A1 (en) 1992-08-09
DE69231538T2 (de) 2001-06-07
IE970857A1 (en) 2000-02-23
CZ33292A3 (en) 1993-03-17
YU48927B (sh) 2002-12-10
CN1036392C (zh) 1997-11-12
NO920489L (no) 1992-08-10
US5571942A (en) 1996-11-05
AU1077592A (en) 1992-08-13
PT712837E (pt) 2001-03-30
RU94044322A (ru) 1996-10-10
CN1063870A (zh) 1992-08-26
KR100219995B1 (ko) 1999-09-01
EP0712837B1 (en) 2000-10-25
CN1140167A (zh) 1997-01-15
RU2057751C1 (ru) 1996-04-10
AU664520B2 (en) 1995-11-16
CZ288067B6 (cs) 2001-04-11
ZA92767B (en) 1993-08-03
YU12992A (sh) 1995-01-31
HU9200396D0 (en) 1992-04-28
HU211848A9 (en) 1995-12-28
ATE151419T1 (de) 1997-04-15
HU225163B1 (en) 2006-07-28
ES2102456T3 (es) 1997-08-01
GR3035190T3 (en) 2001-04-30
DE69231538D1 (de) 2000-11-30
BR9200426A (pt) 1992-10-13
HUT62569A (en) 1993-05-28
AU653197B2 (en) 1994-09-22
HU9500495D0 (en) 1995-04-28
HUT72659A (en) 1996-05-28
NO920489D0 (no) 1992-02-06
KR920016454A (ko) 1992-09-24
DK0498590T3 (da) 1997-05-05
DK0712837T3 (da) 2000-11-20
IL100858A0 (en) 1992-11-15
IL114760A0 (en) 1995-11-27
NZ241495A (en) 1994-10-26
FI920526L (fi) 1992-08-09
JPH04327579A (ja) 1992-11-17
CN1052218C (zh) 2000-05-10
GR3023601T3 (en) 1997-08-29
ATE197145T1 (de) 2000-11-15
RU2105756C1 (ru) 1998-02-27
AU8168794A (en) 1995-02-23
EP0498590A1 (en) 1992-08-12
IL114760A (en) 1997-11-20

Similar Documents

Publication Publication Date Title
NO301825B1 (no) Ringsubstituerte 2-amino-1,2,3,4-tetrahydronaftalener og farmasöytisk preparat inneholdende slike
US6420367B1 (en) Pyrimidine derivatives exhibiting antitumor activity
AU712057B2 (en) Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity
TW495498B (en) Amide derivative and a pharmaceutical composition containing the same as a Ca2+ release activated Ca2+ channel inhibitor
JPWO2002002533A1 (ja) プロパン−１，３−ジオン誘導体
JP2005526137A (ja) アミノテトラリン−誘動尿素のバニロイドｖｒ１受容体調節剤
NZ272812A (en) N-oxazolyl azolyl(alkyl)biphenylsulphonamide derivatives; pharmaceutical compositions
MX2008014959A (es) Compuestos y metodos para modular fxr.
JP2002513387A (ja) 選択的β▲下３▼アドレナリン作動性アゴニスト
JP2000510137A (ja) ドーパミンｄ３受容体のモジュレーターとしてのテトラヒドロイソキノリン誘導体
JP2013517279A (ja) 化合物及び方法
JP2006517564A (ja) Ｎｕｒｒ−１アクチベーターとして有用な複素環化合物
MX2013001202A (es) Compuestos de piridina de anillo fusionado.
JP2003505380A (ja) 新規アミノチアゾール誘導体、それらの製造およびそれらを含有する医薬組成物
WO2000023442A1 (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
JP4146641B2 (ja) ３−アミノ−１−フェニル−１ｈ−［１，２，４］トリアゾールの新規な分岐状置換アミノ誘導体、それらの製造法およびそれらを含む医薬組成物
JPH11240832A (ja) アミド若しくはアミン誘導体
JP4422964B2 (ja) ５員複素環誘導体、その製造法及びその医薬としての使用
KR100248643B1 (ko) 아릴 및 헤테로아릴 알콕시나프탈렌 유도체
JP4098095B2 (ja) ４−アミノピリミジン誘導体
JP2001525398A (ja) 選択的β３アドレナリン作動性アゴニスト
EP2703392B1 (en) 5-membered ring aromatic heterocyclic derivative having npy y5 receptor antagonistic activity
JP2003267870A (ja) 肺高血圧症の予防又は治療剤
IE19970857A1 (en) Ring-substituted 2-amino-1, 2, 3, 4-tetra-hydronaphthalenes and 3-aminochromanes